Whether dosed every 7 or 14 days in pivotal trials
Dosing schedules that fit your lifestyle
High and sustained steady-state FIX levels
*Hemophilia FIX Market Assessment. Third-Party Market Research.
†Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials.
‡Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
§The average dose for people receiving prophylaxis every 7 days was 37 IU/kg.
Connect and learn more about living with and managing hemophilia B
“IDELVION extended dosing means I’ll have more time to study and hang out with friends at college.”
IDELVION offers a wide variety of resources
to help people with hemophilia B.